LDK378

Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity.

1032900-25-6

≥ 2 years

>98% (HPLC)

558.14

C28H36ClN5O3S

Research use only, not for human use.

ALK| FLT3| IGF-1R| Insulin Receptor| STK22D

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

MBS8213909-01 15 nmol

Ask

MBS8213909-02 30 nmol

Ask

MBS8213909-03 5x 30 nmol

Ask

SI207359B 1 Each

Ask

MBS1221545-01 0.02 mg (E-Coli)

Ask

MBS1221545-02 0.02 mg (Yeast)

Ask